David G. Glazer

David focuses on the specialized needs of pharmaceutical, biotechnology, medical device, digital health, and specialty pharmaceutical companies. David brings a background in drug and medical device development and commercialization, early-stage research and development of late-stage product deals, and issues related to the life sciences industry such as indication, field, and territory splitting, and he works on early-stage research collaborations, global alliances, and developing and commercializing products. David’s guidance supports clients at every stage of the development cycle, from clinical to commercial, including complex deals involving gene and cell therapies.

He authors and co-authors articles about the life sciences industry, as well as guest lectures to law students and MBA candidates about licensing in the life sciences industry. For his work in the life sciences field, David has been recognized by numerous publications and ranking organizations, including LMG Life Sciences and Chambers.

• Takeda in its strategic discovery collaboration license agreement with F-star Therapeutics, valued up to $1 billion, that will leverage F-star’s proprietary fully human Fcab™ and tetravalent mAb²™ platforms to research and develop next-generation multi-specific immunotherapies for cancer patients
• Merck in its exclusive license and collaboration agreement with Kelun-Biotech valued up to $9.3 billion to develop seven investigational preclinical antibody-drug conjugates for the treatment of cancer
• American Regent in its acquisition of HBT Labs, Inc., a pharmaceutical company that has a pipeline of generic and 505(b)(2) pharmaceutical products that target various treatment indications including cancer and central nervous system disorders
• Merck in its collaboration agreement valued up to $3.65 billion with Orna Therapeutics to discover, develop, and commercialize circular RNA (oRNA) therapies in multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology, as well as Merck’s $100 million Series B investment in Orna Therapeutics
• Merck in its collaboration and exclusive license agreement valued up to $936 million with Kelun-Biotech for the development, manufacturing and commercialization of an investigational antibody drug conjugate
• Takeda in its strategic research and license collaboration valued up to $400 million with Evozyne, Inc. to research and develop proteins that could be incorporated into next-generation gene therapies for up to four rare disease targets, as well as Evozyne receiving double-digit million dollars in upfront and research funding payments
• Cosette Pharmaceuticals in its acquisition of eight branded commercial products focused on cardiovascular indications from Daichii Sankyo
• Takeda Pharmaceutical Company in its cross-border, multi-asset externalization transaction with Oak Hill Bio under which Takeda will receive an upfront payment, an ownership stake in Oak Hill Bio and potential milestones and royalty payments in exchange for six acquired and licensed programs
• CRISPR Therapeutics in its strategic partnership with Nkarta, Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer
• Merck in its agreement with Gilead to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV
• Dewpoint Therapeutics in its research collaboration with Pfizer for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy. Under the agreement, Dewpoint will receive an upfront payment and will be eligible to receive research, development, and sales milestones payments, totaling up to $239 million should all milestones be achieved. Dewpoint will also be eligible to receive royalties on any approved products
• Nevakar in its exclusive licensing agreement for the commercialization of NVK-002, a proprietary, investigational, preservative-free eye drop to treat myopia in children ages three to 17, valued up to $135 million with Laboratoires Théa
• Dewpoint Therapeutics in its research and development partnership with Volastra Therapeutics to discover novel modulators of biomolecular condensates to prevent cancer progression and metastasis. The partnership will initially be focused on early drug discovery, with the option for future joint development and commercialization
• Bristol Myers Squibb in its agreement valued at more than $2 billion based upon milestones with insitro for the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia
• Eli Lilly in its expanded strategic alliance valued at more than $1 billion involving TYVYT (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine developed by the two companies to be used in the US as well as other markets
• Airon Corp, a privately held company specializing in high-tech pneumatic life support products, in a collaboration with GE Healthcare, one of the world’s largest healthcare companies
• Bristol Myers Squibb in its worldwide research collaboration with Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations. As part of the agreement, BMS will make an upfront payment and Repare will be eligible to receive license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by BMS
• ITF Pharma in its license agreement valued up to $142 million with Starpharma Holdings Limited for the sale and marketing Starpharma’s VivaGel BV therapy, a non-antibiotic therapy for bacterial vaginosis, in the United States
• PTC Therapeutics, Inc. in its acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of a clinical-stage investigational therapy for orphan metabolic diseases
• CRISPR Therapeutics in its license agreement with KSQ Therapeutics using CRISPR technology to enable the CRISPR Therapeutics’ drug discovery engine to achieve higher probabilities of success in drug development. Under the license agreement, CRISPR Therapeutics will gain access to KSQ intellectual property for editing certain novel gene targets in its allogeneic oncology cell therapy programs, and KSQ will gain access to CRISPR Therapeutics’ intellectual property for editing novel gene targets identified by KSQ as part of its current and future engineered tumor infiltrating lymphocyte cell programs.
• Advanz Pharma in its acquisition of rights to two established medicines, Salagen® and Panretin® from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments
• Eli Lilly in its up-to-$560 million partnership with Atomwise to develop up to ten drug targets selected by Lilly, using Atomwise’s artificial intelligence technology
• Merck in its up to $5.76 billion strategic collaboration with Eisai Co. Ltd. for the worldwide co-development and co-commercialization of Eisai's Lenvima (lenvatinib mesylate)
• SQZ Biotechnologies in its $1.37B-plus deal with Roche for a new approach to immuno-oncology where Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development milestones and another $250 million for each new therapy that manages to receive approval and Roche and SQZ will jointly develop anticancer cell therapies that trigger antitumor responses with cell therapies that can target antigens that are beyond the reach of other cell-based adoptive immunity strategies
• Aurobindo in its acquisition from Novartis selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio for $900 million of cash plus $100 million of potential earn-outs
• Eli Lilly in its agreement with NextCure, Inc. for the discovery and development of immuno-oncology therapies to discover novel cancer targets utilizing NextCure's proprietary FIND-IO platform. Under the terms of the agreement, Lilly and NextCure will each receive options to exclusively license antibodies resulting from the collaboration.
• Nevakar Inc. in its $50 million product financing agreement with an affiliate of NovaQuest Capital Management, for the continued development of five differentiated, sterile injectable products
• Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system, and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity.
• Merck in its up to $8.5 billion strategic oncology collaboration with AstraZeneca to co-develop and co-commercialize AstraZeneca's Lynparza (olaparib) and AstraZeneca’s selwnetinib
• Nevakar Inc. in its exclusive licensing agreement with Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the U.S. and Canada
• Regeneron in its agreement with bluebird bio to develop and commercialize new cell therapies for cancer. As part of the transaction, Regeneron made a $100 million investment in bluebird bio common stock.
• Merck in its strategic collaboration and license agreement with Moderna to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck’s established leadership in immuno-oncology with Moderna’s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers.
• AbbVie in its global collaboration and license agreement with Halozyme to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform. Under the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling approximately $130 million for each of up to nine collaboration targets and tiered royalties if products under the collaboration are commercialized.
• Merck in its license and collaboration agreement with Moderna for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA)
• Ironwood in its licensing agreement with AstraZeneca for the exclusive US rights to Zurampic® pursuant to which Ironwood acquired exclusive US rights to Zurampic and the exclusive US rights to the fixed-dose combination of lesinurad and allopurinol. Ironwood will pay AstraZeneca sales-related and other milestone payments of up to $265 million and tiered single-digit royalties on Product Sales
• Merck in its $14.2 billion agreement to sell its consumer care business to Bayer
• Merck in its collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase modulators, under which Bayer receives a $1 billion up-front payment with the potential for additional milestone payments
• Celgene in its drug-discovery collaboration with Cancer Research Technology (CRT), to discover, develop and commercialize new anti-cancer treatments centered on mRNA translation
• Merck in its joint venture with Sun Pharmaceutical Industries, a leading Indian multinational pharmaceutical company, to develop, manufacture and commercialize new combinations and formulations of innovative, branded generics in the emerging markets
• BTG in the sale of its brachytherapy business to Eckert & Ziegler
• Lumiphore in its agreement with Algeta for worldwide license to Lumiphore’s patented chelator technology to be used for cancer therapeutics
• Lundbeck in its commercial rights agreement with Cephalon to register and commercialize several Cephalon products including Fentora, Provigil, Treanada, Trisenox, Myocet, and Nuvigil in Canada and Latin America
• BTG in the $180 million acquisition of EKOS Corporation
• MEI Pharma in its acquisition from S*BIO of the rights to Pracinostat, a clinical stage oncology drug
• Eli Lilly in its multi-year, multibillion dollar clinical and research agreements with Covance Inc.
• LifeNet Health in its acquisition of Northwest Tissue Services from Puget Sound Blood Center
• An international specialty pharma company in its multi­million dollar transformative manufacturing arrangement, whereby it transitioned the manufacture of several specialty pharmaceutical products to a contract manufacturer
• NPS Pharmaceuticals in the restructuring and sale of its mGluRs collaboration with AstraZeneca
• Represented a biotechnology company in negotiation of complete supply chain agreements, including with two API manufacturers, two bulk drug manufacturers, two packaging providers, and the supply agreement with its collaboration partner for the finished product in both the United States and Europe
• Novo Nordisk in its agreement with Sciele Pharma for Sciele to market Prandin® and, upon approval by the US Food and Drug Administration, PrandiMet
• Assisted a European/US company to negotiate clinical trial agreements with more than 25 sites in the U.S. in neuropharm product area.
• A biotechnology company in its master services agreement and clinical trial agreements with an international clinical research organization
• Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD